Shares of Alkermes (ALKS) were up 30 percent in 2015 and the biotech company’s strong pipeline for psychiatric drugs bodes well for another strong year in the market, said Michael Kramer, CEO of Mott Capital. 'Their lead drug for a major depressive disorder should have phase three results coming in the first quarter of this year,' said Kramer. 'Previous studies had indicated that patients who had major depressive disorders showed results within in seven days which is very impressive.' Kramer is also constructive on Tesla (TSLA), which saw its stock rise around 13 percent in 2015. The electric automaker’s shares sank almost 7 percent on Monday after the company said it delivered 50,580 vehicles in 2015, including 17,400 in the fourth quarter. The total surpassed Tesla’s guidance of 50,000 cars, yet Wall Street analysts were hoping for a number closer to 55,000. TheStreet's Gregg Greenberg has details from New York.
More from Emerging Markets
Indonesian stocks have done poorly this year, but these nine stocks could rate attention if investors rediscover the market.
A U.S. dollar that is rising in value against most other currencies is creating a huge problem for a world inundated with dollar-priced debt.
As global markets breached their key 200-day moving averages and with uptrends being tested, there were rumours of globally coordinated central bank easing.
From bonds to energy to emerging markets, an examination of what might be hot and what might not.
Shares of Cresud have been hammered by a big political shift in Argentina, which makes the farming name a value play not for the faint of heart.